

**Amendments to the Specification:**

Please replace the second paragraph on page 11 with the following amended paragraph:

By closer standardisation of individual patient dosaging rate and blood/blood-serum level response, as well as dosaging and response ~~para~~ parameters for patient groups, monitoring requirements may be reduced, thus substantially reducing the cost of therapy.

Please replace the third complete paragraph on page 19 with the following amended paragraph:

When (d) is present and is a trans-esterification product of a natural vegetable oil triglyceride and a polyalkylene ~~plyol~~ polyol (for example a Labrafil), (d) is suitably present in an amount of up to about 50%, preferably from about 20 to about 40%, most preferably about 30%, based on the total weight of the composition.